doi: 10.3389/fendo.2026.1801203 Received 01 February 2026 Revised 18 March 2026 Accepted 23 March 2026 Published 13 April 2026 Volume 17 - 2026 Edited by Emi Sato, Fukuoka University, Japan Reviewed by Zilu Chen, Rutgers, The State University of New Jersey, United States Jenna Ingram, Mount Sinai Hospital, United States Updates Copyright 2026 Chiang, Li, Fang, Liu, Wu and Tsai
In this Analysis, we searched for relevant literature on the effects of GLP-1RAs across a range of illnesses, gathering and describing the available pre-clinical and mechanistic (278 studies) and clinical (96 studies) evidence for cognitive disorders, substance-use disorders, psychotic disorders, mood and anxiety disorders, eating disorders, and others
Support body fat reduction
Questions for Cramer
Other neurological illnesses like Lyme disease weaken when your body experiences higher levels of glutathione